The one-year development project agreement on behalf of a customer is worth
about USD 100,000. The project will adapt Genovis’ products from the protein
characterization portfolio to the customer’s technology platform.
“We look forward to launching this initiative together with our customer. This
project demonstrates the interest in Genovis’ unique products and is a
recognition of our skills and experience in characterizing antibody-based
drugs,” says Sarah Fredriksson, CEO of Genovis.
